AI assistant
Sending…
Silence Therapeutics plc — Director's Dealing 2025
May 27, 2025
33536_dirs_2025-05-27_4186ef4b-4c93-4816-92c4-85c75e2965eb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Silence Therapeutics plc (SLN)
CIK: 0001479615
Period of Report: 2025-05-22
Reporting Person: Griffiths Richard Ian (10% Owner)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-05-22 | American Depositary Shares | $5.04 | P | 19174 | Acquired | Ordinary Shares (57522) | Direct | |
| 2025-05-23 | American Depositary Shares | $4.92 | P | 17187 | Acquired | Ordinary Shares (51561) | Direct |
Footnotes
F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.
More from Silence Therapeutics plc
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 18
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Proxy Solicitation & Information Statement
2026
Apr 29
Director's Dealing
2026
Feb 13
Major Shareholding Notification
2026
Feb 9
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6